PERK Inhibition Mitigates Restenosis and Thrombosis: A Potential Low-Thrombogenic Antirestenotic Paradigm

Bowen Wang; Mengxue Zhang; Go Urabe; Yitao Huang; Guojun Chen; Debra Wheeler; David J. Dornbos; Allyson Huttinger; Shahid M. Nimjee; Shaoqin Gong; Lian Wang Guo; K. Craig Kent

doi:10.1016/j.jacbts.2019.12.005

PERK Inhibition Mitigates Restenosis and Thrombosis: A Potential Low-Thrombogenic Antirestenotic Paradigm

Bowen Wang
, Mengxue Zhang
, Go Urabe
, Yitao Huang
, Guojun Chen
, Debra Wheeler
, David J. Dornbos
, Allyson Huttinger
, Shahid M. Nimjee
, Shaoqin Gong
, Lian Wang Guo
, K. Craig Kent

Producción científica: Article › revisión exhaustiva

25 Citas (SciVal)

Resumen

Developing endothelial-protective, nonthrombogenic antirestenotic treatments has been a challenge. A major hurdle to this has been the identification of a common molecular target in both smooth muscle cells and endothelial cells, inhibition of which blocks dysfunction of both cell types. The authors’ findings suggest that the PERK kinase could be such a target. Importantly, PERK inhibition mitigated both restenosis and thrombosis in preclinical models, implicating a low-thrombogenic antirestenotic paradigm.

Idioma original	English
Páginas (desde-hasta)	245-263
Número de páginas	19
Publicación	JACC: Basic to Translational Science
Volumen	5
N.º	3
DOI	https://doi.org/10.1016/j.jacbts.2019.12.005
Estado	Published - mar 2020

Nota bibliográfica

Publisher Copyright:
© 2020 The Authors

Financiación

This work was supported by National Institutes of Health grants R01HL143469, R01HL129785 (to Drs. Gong, Guo, and Kent), R01HL133665 (to Dr. Guo), K25CA166178 (to Dr. Gong), and American Heart Association pre-doctoral awards 17PRE33670865 (to Dr. Zhang) and 16PRE30160010 (to Dr. Wang). The authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Financiadores	Número del financiador
National Institutes of Health (NIH)	R01HL129785, K25CA166178, R01HL143469
National Heart, Lung, and Blood Institute (NHLBI)	R01HL133665
American the American Heart Association	16PRE30160010, 17PRE33670865

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

Acceder al documento

10.1016/j.jacbts.2019.12.005

Otros archivos y enlaces

Citar esto

@article{35e84ff85d534276807a06525d982f2b,

title = "PERK Inhibition Mitigates Restenosis and Thrombosis: A Potential Low-Thrombogenic Antirestenotic Paradigm",

abstract = "Developing endothelial-protective, nonthrombogenic antirestenotic treatments has been a challenge. A major hurdle to this has been the identification of a common molecular target in both smooth muscle cells and endothelial cells, inhibition of which blocks dysfunction of both cell types. The authors{\textquoteright} findings suggest that the PERK kinase could be such a target. Importantly, PERK inhibition mitigated both restenosis and thrombosis in preclinical models, implicating a low-thrombogenic antirestenotic paradigm.",

keywords = "PERK, endothelial cells, restenosis, smooth muscle cells, thrombosis",

author = "Bowen Wang and Mengxue Zhang and Go Urabe and Yitao Huang and Guojun Chen and Debra Wheeler and Dornbos, \{David J.\} and Allyson Huttinger and Nimjee, \{Shahid M.\} and Shaoqin Gong and Guo, \{Lian Wang\} and Kent, \{K. Craig\}",

note = "Publisher Copyright: {\textcopyright} 2020 The Authors",

year = "2020",

month = mar,

doi = "10.1016/j.jacbts.2019.12.005",

language = "English",

volume = "5",

pages = "245--263",

number = "3",

}

TY - JOUR

T1 - PERK Inhibition Mitigates Restenosis and Thrombosis

T2 - A Potential Low-Thrombogenic Antirestenotic Paradigm

AU - Wang, Bowen

AU - Zhang, Mengxue

AU - Urabe, Go

AU - Huang, Yitao

AU - Chen, Guojun

AU - Wheeler, Debra

AU - Dornbos, David J.

AU - Huttinger, Allyson

AU - Nimjee, Shahid M.

AU - Gong, Shaoqin

AU - Guo, Lian Wang

AU - Kent, K. Craig

PY - 2020/3

Y1 - 2020/3

N2 - Developing endothelial-protective, nonthrombogenic antirestenotic treatments has been a challenge. A major hurdle to this has been the identification of a common molecular target in both smooth muscle cells and endothelial cells, inhibition of which blocks dysfunction of both cell types. The authors’ findings suggest that the PERK kinase could be such a target. Importantly, PERK inhibition mitigated both restenosis and thrombosis in preclinical models, implicating a low-thrombogenic antirestenotic paradigm.

AB - Developing endothelial-protective, nonthrombogenic antirestenotic treatments has been a challenge. A major hurdle to this has been the identification of a common molecular target in both smooth muscle cells and endothelial cells, inhibition of which blocks dysfunction of both cell types. The authors’ findings suggest that the PERK kinase could be such a target. Importantly, PERK inhibition mitigated both restenosis and thrombosis in preclinical models, implicating a low-thrombogenic antirestenotic paradigm.

KW - PERK

KW - endothelial cells

KW - restenosis

KW - smooth muscle cells

KW - thrombosis

UR - https://www.scopus.com/pages/publications/85081632787

UR - https://www.scopus.com/pages/publications/85081632787#tab=citedBy

U2 - 10.1016/j.jacbts.2019.12.005

DO - 10.1016/j.jacbts.2019.12.005

M3 - Article

AN - SCOPUS:85081632787

SN - 2452-302X

VL - 5

SP - 245

EP - 263

JO - JACC: Basic to Translational Science

JF - JACC: Basic to Translational Science

IS - 3

ER -

PERK Inhibition Mitigates Restenosis and Thrombosis: A Potential Low-Thrombogenic Antirestenotic Paradigm

Resumen

Nota bibliográfica

Financiación

ASJC Scopus subject areas

Acceder al documento

Otros archivos y enlaces

Huella

Citar esto